MedImmune Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JS Ogrady who wrote (125)	7/10/1998 11:58:00 AM
From: Diane	Read Replies (1) of 416

Good news from Briefing.com: MedImmune Inc. (MEDI) 62 3/4 -1 1/8: Adams Harkness initiates coverage of developer and marketer of therapeutics and vaccines with "buy" and a year-end price target of $83; company granted FDA approval for Synagis, a monoclonal antibody to replace RespiGam, expects Synagis sales of $162 mln in FY98, $251 mln in FY99, $326 mln in FY00 and $429 mln in FY01; expects company to earn $0.08 in FY98 and $1.80 in FY99.....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next